Study of Azacitidine and Durvalumab in Advanced Solid Tumors

NCT02811497 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Microsatellite Stable Colorectal Carcinoma
Platinum Resistant Epithelial Ovarian Cancer Type II
Estrogen Receptor Positive and HER2 Negative Breast Cancer

Interventions

DRUG: Azacitidine
DRUG: Durvalumab

Sponsor

University Health Network, Toronto